OP0104

The presence of blood in the joint and the immediate molecular response in synovial fluid are independently associated with worse clinical outcomes at 2 years after human knee injury

Cesar Garriga1,2, Megan Goff1, Kirsten Leyland3,4, Erin Paterson1, Renata Hrusecka1, Benjamin Hamid4, Lesley Honeyfield5, Andy Williams4,5, Fiona Watt1, 1University of Oxford, Arthritis Research UK Centre for Osteoarthritis Pathogenesis Kennedy Institute of Healthcare NHS Trust, St Mary's Hospital, London, United Kingdom; 2University of Oxford, Botnar Research Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom; 3University of Oxford, Oxford University Centre for Osteoarthritis Pathogenesis; 4Institute of Orthopaedics and Musculoskeletal Sciences, London, United Kingdom; 5OsteoRheuma AG, Bern, Switzerland

Background: Knee injury increases the risk of knee osteoarthritis at least 7 fold. We have shown an immediate inflammatory response to acute knee injury which is measurable both in mouse joint tissues and also in human synovial fluid (SF). Objectives: We set out to test whether the measured immediate inflammatory protein response in SF or plasma/serum was associated with knee symptoms at 2 years after knee injury.

Methods: 150 individuals were recruited within 8 weeks of a significant acute knee injury to the Knee Injury Cohort at the Kennedy (KICK; REC 10/H0805/39; NCT02667756) from 2011-2014. The primary outcome was the Knee Injury and Osteoarthritis Outcome Score (KOOS)-4 at 2 years (a composite measure of 4 KOOS domains, where 100 is normal knee health). Baseline covariates were sex, age, body mass index (BMI), clinical effusion, SF blood staining, radiographic Kellgren-Lawrence (KL) Grade. 123/150 (82%) were male, mean age (SD) 27(8) years and BMI 26(4) kg/m2. Mean KOOS4 increased from 38(18) at baseline to 70(18) at 2 years. 64 (43%) had KL 0/1, 24 (16%) KL 2 and 11 (7%) KL 3, 75 (50%) medium/large effusion and 50 (33%) moderate/severe SF blood staining.

Adjusted simple linear model (by baseline KOOS4) and fully adjusted model (by baseline KOOS4, blood staining and effusion) for the association of biomarkers with KOOS4:

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Coef (95% CI)</th>
<th>P</th>
<th>Coef (95% CI)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCP-1</td>
<td>-0.020</td>
<td>0.0005</td>
<td>-0.015</td>
<td>0.01</td>
</tr>
<tr>
<td>FGF-2</td>
<td>-0.047</td>
<td>0.02</td>
<td>-0.021</td>
<td>0.28</td>
</tr>
<tr>
<td>IL-6</td>
<td>-0.0006</td>
<td>0.01</td>
<td>-0.0005</td>
<td>0.02</td>
</tr>
<tr>
<td>TGFb</td>
<td>-0.0028</td>
<td>0.03</td>
<td>0.0018</td>
<td>0.14</td>
</tr>
<tr>
<td>IL-18</td>
<td>-0.078</td>
<td>0.03</td>
<td>-0.02</td>
<td>0.75</td>
</tr>
</tbody>
</table>

Conclusion: Those with higher levels of SF MCP-1 and IL-6 at the time of injury had a significantly worse outcome at 2 years. The presence of haemarthrosis, clinical effusion and impairment/pain at the time of injury were also independent predictors of outcome. In contrast, no baseline plasma/serum markers were associated with outcome. Stratifying individuals at high risk of persistent symptoms after knee injury may enable clinical trials of interventions to prevent or treat PTOA.

Disclosure of interests: Cesar Garriga: None declared, Megan Goff: None declared, Kirsten Leyland: None declared, Erin Paterson: None declared, Renata Hrusecka: None declared, Benjamin Hamid: None declared, Lesley Honeyfield: None declared, Keshthra Satchithananda: None declared, Adrian Lim: None declared, Nigel Arden Grant/research support from: Grants from BIOERICA, and from MERCK, Consultant for: Personal fees from Flexion, from Regeneron, from Freshfields Bruckhaus Deringer, outside the submitted work, Andrew Judge Consultant for: Received consultancy fees, lecture fees and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol and Freshfields Bruckhaus. Member of Deringer Data Safety and Monitoring Board for Anthera Pharmaceuticals, Inc. Consultancy for Freshfields Bruckhaus Deringer, Andy Williams: None declared, Fiona Watt Grant/research support from: Pfizer and Astellas clinical study grants (not in this area)


OP0105-HPR

The riddle of adherence

Yomei Shae1, Delphine Couvoisier1, Almut Scherer2, Adrian Ciurea3, Thomas Lehmann4, Veronika Jaege5, Ulrich Walker6, Axel Finck1, 1University Hospitals of Geneva, Geneva, Switzerland; 2SCQM Foundation, Zürich, Switzerland; 3University Hospital of Zürich, Zürich, Switzerland; 4OsteoRheuma Bern AG, Bern, Switzerland; 5University of Basel, Basel, Switzerland; 6University Hospital of Basel, Basel, Switzerland

Background: From 2015 to 2018, the Swiss Clinical Quality Management in Rheumatic Diseases registry (SCQM) offered two mobile apps, iDialog and CO-MPASS, allowing patients to track disease and health status between rheumatology visits. Both apps are linked to the registry database, providing patients and physicians extra information to guide disease management decisions.

Objectives: To investigate the effect of SCQM app use on shared decision making (SDM) and disease management.

Methods: Patients were assigned to a cross sectional survey about satisfaction with SDM [1], disease management, and app use (February-December 2018). Patients’ demographic data and longitudinal data on disease status, health status, and medication use was extracted from the SCQM database. Analyses included patients diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA) who had 1) used an SCQM app for at least 6 months and discussed app data with their physician (app + discussion group), 2) used an SCQM app for at least 6 months and did not discuss app data with their physician (app only group), or 3) did not use any SCQM app (non-app users).

We compared the 3 groups by conducting logistic regressions for the following dichotomized outcomes: maximum satisfaction with SDM and physician following the app; satisfaction with app data; and 3) did not use any SCQM app (non-app users).

Results: 1924 patients were included in the analyses. App users were younger than non-app users (Table 1). In adjusted analyses (Table 2), satisfaction rates were higher in the app + discussion group (p<0.05) compared to non-app users, but not for the app only group. The app only group had higher rates of treatment intensification in the last 6 months of followup (p=0.02) compared to non-app users. Although the app only and app + discussion groups had higher adjusted rates of the other disease management outcomes compared to non-app users, the effects were not statistically significant.

Conclusion: App users who communicated with their rheumatologist about their app data were more satisfied with their physicians than app users who did not communicate about their app data and non-app users. Provision of apps that increase the frequency of disease monitoring may have limited impact on patient satisfaction with care and disease management processes without integration of app use into existing care processes.

Disclosure of interests: All authors have completed the ICMJE uniform disclosure form at: http://www.icmje.org/coiDisclosure.pdf and declare: None declared, Nigel Arden Grant/research support from: Grants from BIOERICA, and from MERCK, Consultant for: Personal fees from Flexion, from Regeneron, from Freshfields Bruckhaus Deringer, outside the submitted work, Andrew Judge Consultant for: Received consultancy fees, lecture fees and honoraria from Servier, UK Renal Registry, Oxford Craniofacial Unit, IDIAP Jordi Gol and Freshfields Bruckhaus. Member of Deringer Data Safety and Monitoring Board for Anthera Pharmaceuticals, Inc. Consultancy for Freshfields Bruckhaus Deringer, Andy Williams: None declared, Fiona Watt Grant/research support from: Pfizer and Astellas clinical study grants (not in this area)